A startling revelation about weight-loss drugs has emerged, challenging the conventional wisdom surrounding their long-term use.
The BMJ analysis, a comprehensive review of existing studies, has raised critical questions about the sustainability of weight-loss medication without concurrent lifestyle support.
Here's the crux: stopping weight-loss drugs leads to a rapid rebound effect, with patients regaining weight at an alarming rate. On average, individuals regain 0.4 kg per month, and all lost weight is likely to be regained within a mere 1.7 years.
But here's where it gets controversial...
The analysis also revealed that improvements in cardiometabolic risk markers, such as blood pressure, cholesterol, and diabetes risk, return to pre-treatment levels within 14 months of discontinuing medication.
Weight regain occurs almost four times faster after stopping pharmacological treatment compared to behavioral weight-loss programs focused on diet and physical activity.
Associate Professor Dominika Kwasnicka, a behavioral scientist and public health researcher, sheds light on this issue:
"From a behavioral science perspective, this review highlights a key limitation of relying solely on weight management medications. While highly effective during use, obesity is a chronic condition influenced by behaviors, environments, and ongoing support."
Professor Kwasnicka emphasizes that medications primarily target biological pathways and do not inherently establish the behavioral or systemic changes necessary for long-term weight loss.
The findings have significant implications for healthcare professionals and policymakers, especially as the use of GLP-1 receptor agonists continues to rise.
The controversy deepens as real-world evidence suggests that approximately half of patients discontinue GLP-1 RA therapy within 12 months, often due to cost, tolerability, or the misconception that treatment is short-term.
The analysis included 37 randomized and observational studies, involving 9341 adults, with an average treatment duration of 39 weeks and a mean follow-up of 32 weeks post-treatment.
Despite limitations, the consistent results across three analytical approaches strengthen the confidence in these findings.
The authors caution against short-term use of weight-management medications and emphasize the need for cost-effective strategies to support long-term weight control.
And this is the part most people miss...
Pharmacotherapy alone is unlikely to provide sustained benefits, and primary prevention remains crucial. As obesity is a chronic and relapsing condition, prolonged treatment with weight management medications may be necessary to maintain health benefits.
In a linked editorial, Associate Professor Qi Sun argues that GLP-1 receptor agonists should not be viewed as a definitive cure for obesity. He highlights the importance of healthy dietary and lifestyle practices as the foundation of obesity management, with medications serving as adjuncts.
Professor Sun suggests adopting healthy diets and lifestyles proven effective in preventing excess weight regain, and further research is needed to understand weight regain after discontinuing GLP-1 receptor agonists.
The benefits of managing obesity with dietary and lifestyle practices extend beyond weight control, leading to numerous additional health benefits.
Professor John B Dixon agrees, emphasizing that while the new obesity management medications have improved efficacy, they do not cure the underlying disordered energy balance.
So, what's the takeaway?
Weight-loss drugs can be highly effective, but their long-term sustainability without lifestyle changes is questionable. The analysis highlights the need for a comprehensive approach, combining pharmacotherapy with behavioral support and realistic discussions about treatment duration.
What are your thoughts on this controversial topic? Feel free to share your opinions and experiences in the comments below!
